Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates

Journal of Urology

Volumn 161, Issue 3, 1999, Pages 799-804

  Crew, Jeremy P ^a   O'Brien, Tim ^a   Bicknell, Roy ^a   Fuggle, Sue ^a   Cranston, David ^a   Harris, Adrian L ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis factor; Bladder; Bladder neoplasms; Recurrence; Urine

Indexed keywords

TUMOR MARKER; VASCULOTROPIN;

ACCURACY; ARTICLE; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CADAVER; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOSCOPY; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; URINALYSIS;

EID: 0032854988     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)61772-5     Document Type: Article

References (35)

1. Folkman, J.: What is the evidence that tumors are angiogenesis dependent? New Engl. J. Med., 285: 82, 1990.
2. Folkman, J.: Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nature Med., 1: 27, 1995.
3. Bochner, B. H., Cote, R. J., Groshen, S., Esrig, D., Freeman, J. A., Weidner, N., Chen, S.-C., Skinner, D. G. and Nichols, P. W.: Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J. Natl. Cancer Inst., 87: 1603, 1995.
4. Ferrara, N. and Davis-Smyth, T. D.: The biology of vascular endothelial growth factor. Endocr. Rev., 10: 4, 1997.
5. O'Brien, T. S., Cranston, D., Fuggle, S., Bicknell, R. and Harris, A. L.: Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res., 55: 510, 1995.
6. Zhang, H.-T., Craft, P., Scott, P. A. E., Ziche, M., Weich, H., Harris, A. L. and Bicknell, R.: Enhancement of tumor growth and vascularity by transfection of vascular endothelial growth factor into MCF-7 cells breast carcinoma cells. J. Natl. Cancer Inst., 87: 213, 1995.
7. Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S. and Ferrara, N.: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature, 362: 841, 1993.
8. Skobe, M., Rockwell, P., Goldstein, N., Vosseler, S. and Fusenig, N. E.: Halting angiogenesis suppresses carcinoma cell invasion. Nature Med., 3: 1222, 1997.
9. Crew, J. P., O'Brien, T. S., Bradburn, M., Fuggle, S., Bicknell, R., Cranston, D. and Harris, A. L.: Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res., 57: 5281, 1997.
10. Rasmussen, H. H., Orntoft, T. F., Wolf, H. and Celis, J. E.: Toward a comprehensive database of proteins from the urine of patients with bladder cancer. J. Urol., 155: 2113, 1996.
11. Chodak, G., Schemer, C. and Zetter, B.: Urine from patients with transitional cell carcinoma stimulates migration of capillary endothelial cells. New Engl. J. Med., 305: 869, 1981.
12. Chodak, G. W., Hospelhorn, V., Judge, S. M., Mayforth, R., Koeppen, H. and Sasse, J.: Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer. Cancer Res, 48: 2083, 1988.
13. O'Brien, T. S., Smith, K., Cranston, D., Fuggle, S., Bicknell, R. and Harris, A. L.: Urinary basic fibroblast growth factor is elevated in patients with bladder cancer and benign prostatic hypertrophy. Brit. J. Urol., 76: 311, 1995.
14. Chopin, D. K., Caruelle, J. P., Colombel, M., Palcy, S., Ravery, V., Caruelle, D., Abbou, C. C. and Barritault, D.: Increased immunodetection of acidic fibroblast growth factor in bladder cancer detectable in urine. J. Urol., 150: 1126, 1993.
15. Joseph, A., Weiss, G. H., Jin, L., Fuchs, A., Chowdhury, S., O' Shaugnessy, P., Goldberg, I. D. and Rosen, E. M.: Expression of scatter factor in human bladder carcinoma. J. Natl. Cancer Inst., 87: 372, 1995.
16. Sacks, N. P. M., Smith, K., Norman, A. P., Greenall, M., Lejeune, S. and Harris, A. L.: Cathepsin D levels in primary breast cancer: relationship with epidermal growth factor receptor, oestrogen receptor and axillary node status. Eur. J. Cancer, 29A: 426, 1993.
17. Bradford, M. M.: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem., 72: 248, 1976.
18. Chomczynski, P. and Saachi, N.: Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162: 156, 1987.
19. Scott, P. A. E., Smith, K., Bicknell, R. and Harris, A. L.: A reliable external control for ribonuclease protection assays. Nucleic Acid Res., 25: 1305, 1997.
20. Fitzpatrick, J. M.: Superficial bladder cancer: natural history, evaluation and management. AUA Update Series, vol. VIII, lesson 40, 1989.
21. Nguyen, M., Watanabe, H., Budson, A. E., Richie, J. P., Hayes, D. F. and Folkman, J.: Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J. Natl. Cancer. Inst., 86: 356, 1994.
22. Plate, K. H., Breier, G., Weich, H. A., Mennel, H. D. and Risau, W.: Vascular endothelial growth factor and glioma angiogenesis - coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int. J. Cancer, 59: 520, 1992.
23. Kawai, N., Okamura, T., Tozawa, K., Akita, H. and Kohri, K.: Immunohistological study of vascular endothelial growth factor (VEGF) in prostate cancer. J. Urol., part 2, 157: 148, abstract 581, 1997.
24. Nguyen, M., Watanabe, H., Budson, A., Richie, J. and Folkman, J.: Elevated levels of the angiogenic peptide basic fibroblast growth factor in the urine of bladder cancer patients. J. Natl. Cancer Inst., 85: 241, 1993.
25. Wagner, U., Sauter, G., Moch, H., Novotna, H., Epper, R., Mihaysch, J. and Waldman, F. M.: Pattern of p53, erbB-2, and EGF-r expression in premalignant lesions of the urinary bladder. Hum. Path., 26: 970, 1995.
26. Witjes, J. A., Umbas, R., Debruyne, F. M. J. and Schalken, J. A.: Expression of markers for transitional cell carcinoma in normal bladder mucosa of patients with bladder cancer. J. Urol., 154: 2185, 1995.
27. Schmitz-Drager, B. J., Van Roeyen, C. R., Grimm, O., R., Gerharz, C. D., Decken, K., Schultz, W. A., Bultel, H., Makri, D., Ebert, T. and Ackermann, R.: p53 accumulation in precursor lesions and early stages of bladder cancer. World J. Urol., 12: 79, 1994.
28. Ritchie, J. P., Shipley, W. U. and Yagoda, A.: Cancer of the bladder. In: Cancer: Principles and Practice of Oncology, 3rd ed. Edited by V. T. DeVita, S. Hellman and S. A. Rosenberg. Philadelphia: Lippincott, 1989.
29. Harris, A. L. and Neal, D. E.: Bladder cancer - field versus clonal origin. New Engl. J. Med., 11: 759, 1992.
30. Hanahan, D. and Folkman, J.: Patterns and emerging mechanisms of the angiogenic switch during tumourigenesis. Cell, 86: 353, 1996.
31. Chodak, G., Haudenschild, C., Gittes, R. and Folkman, J.: Angiogenic activity of a marker of neoplastic and preneoplastic lesions of the human bladder. Ann. Surg., 192: 762, 1980.
32. Dirix, L. Y., Vermeulen, P. B., Pawinski, A., Prove, A., De Pooter, C., Martin, M. and Van Oosterom, A. T.: Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Brit. J. Cancer, 76: 238, 1997.
33. Ro, J. Y., Straerkel, G. A. and Ayala, A. G.: Cytologic and histologic features of superficial bladder cancer. Urol. Clin. N. Amer., 19: 435, 1992.
34. Murphy, W. M.: Current status of urinary cytology in the evaluation of bladder neoplasms. Hum. Path., 21: 886, 1990.
35. Raghavan, D., Shipley, W. and Garnick, M.: Biology and management of bladder cancer. New Engl. J. Med., 322: 1129, 1990.